AR004501A1 - Una sal de orotato de un compuesto triazol - Google Patents

Una sal de orotato de un compuesto triazol

Info

Publication number
AR004501A1
AR004501A1 ARP960103666A AR10366696A AR004501A1 AR 004501 A1 AR004501 A1 AR 004501A1 AR P960103666 A ARP960103666 A AR P960103666A AR 10366696 A AR10366696 A AR 10366696A AR 004501 A1 AR004501 A1 AR 004501A1
Authority
AR
Argentina
Prior art keywords
amino
cyano
individual
lower alkyl
cancer
Prior art date
Application number
ARP960103666A
Other languages
English (en)
Original Assignee
Tactical Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tactical Therapeutics Inc filed Critical Tactical Therapeutics Inc
Publication of AR004501A1 publication Critical patent/AR004501A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para prevenir o inhibir el crecimiento de un cáncer en un individuo, que consiste en administrar a un individuo que lo necesite, unacantidad terapéuticamente efectiva de una composición que comprende una sal de 5-aminoimidazol-4 -carboxamida y/o 5-amino ó 1,2,3-triazoles 5-amino oaminosubstituidos de la fórmula (I), 5-amino-1H-imidazol + sales -4- carboxamida, y (II), en la cual un ácido orgánico o un ácido inorgánico estáunido al R2 y en donde R1 es (III), en donde p es 0 a 2; m es 0 a 4; y n es 0 a 5; X es O, S, SO, SO2, CO, CHCN, CH2 ó C=NR6, en donde R6 es hidrógeno, alquiloinferior, hidroxi, alcoxi inferior, amino, alquilamino inferior, dialquilamino inferior o ciano; y R4 y R5 son independientementeha lógeno, ciano,trifluorometil, alcanoil inferior, nitro, alquil inferior, alcoxi inferior, carboxi, carbalcoxi inferior, trifluorometoxi, acetamido, alquiltio inferior,alquilsulfinil inferior, alquilsulfonil inferior, triclorovinilo,trifluorometiltio, trifluorometil sulfinilo ó trifluorometil sulfonilo; R2 esamino, mono o dialquil amino inferior, acetamido, acetimido, ureido,formamido, formimido o guanidino; y R3 es carbamoilo, ciano, carbazoilo, amidino o N-hidroxicarbamoilo;en donde los grupos alquil inferior, que contienen alquil inferior, alcoxi inferior, y alcanoil inferior, contienenn de 1 a 3 átomos decarbono, en la preparación de una composición administrable a un individuo como un agente para prevenir o inhib irel crecimiento de un cáncer. Se describenmétodos y composiciones para la prevención y/o inhibición de neoplasmas metastásicos primario y secundario. Individuos con un alto riesgo de desarrollode neoplasias y pacientes con cáncer que se som eten aterapias convencionales pueden ser tratados con una dosis efectiva de una sal de aminoimidazol
ARP960103666A 1995-07-21 1996-07-19 Una sal de orotato de un compuesto triazol AR004501A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/505,439 US5728707A (en) 1995-07-21 1995-07-21 Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US08/684,297 US5861406A (en) 1995-07-21 1996-07-18 Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles

Publications (1)

Publication Number Publication Date
AR004501A1 true AR004501A1 (es) 1998-12-16

Family

ID=24010320

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960103666A AR004501A1 (es) 1995-07-21 1996-07-19 Una sal de orotato de un compuesto triazol

Country Status (4)

Country Link
US (2) US5728707A (es)
KR (1) KR100477910B1 (es)
CN (1) CN101273988B (es)
AR (1) AR004501A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP0840608B1 (en) * 1995-07-21 2004-10-06 Savvipharm Inc. Orotate salts of 5-amino or substituted amino 1,2,3-triazoles for treatment of neoplasms
US6184227B1 (en) * 1995-07-21 2001-02-06 Savvipharm Inc. Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
EP1100507B1 (en) * 1998-07-31 2007-01-24 Sacks, Meir S. Use of a combination comprising a precursor of uric acid and antioxidant for the treatment of neurodegenerative deseases
EA010263B1 (ru) * 1999-11-08 2008-06-30 Те Юниверсити Оф Теннесси Рисерч Корпорейшн Способ химиопрофилактики рака предстательной железы
EP1278544A4 (en) * 2000-04-12 2004-08-18 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
US6462017B1 (en) * 2000-05-01 2002-10-08 Sciclone Pharmaceuticals, Inc. Method of reducing side effects of chemotherapy in cancer patients
CU22999A1 (es) * 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
EP1401477A4 (en) * 2001-05-25 2005-02-02 Human Genome Sciences CHIMIOKINE BETA-1 HYBRID PROTEINS
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US7531560B2 (en) * 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
US7601834B2 (en) * 2005-02-22 2009-10-13 Savvipharm Inc Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
US8017129B2 (en) * 2006-06-15 2011-09-13 SciClone Pharmaceuticals International Ltd Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
US7750018B2 (en) * 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
US20080300166A1 (en) * 2007-06-01 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of Melanoma with Alpha Thymosin Peptides
US8461192B2 (en) * 2007-09-13 2013-06-11 The University Of South Florida Method of selectively inhibiting PKCiota
CN104817507A (zh) * 2009-09-04 2015-08-05 巧妙疗法股份有限公司 用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法
US9089570B2 (en) 2010-09-03 2015-07-28 Tactical Therapeutics Inc Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
KR102443370B1 (ko) 2015-11-20 2022-09-15 동우 화인켐 주식회사 실리콘 질화막 식각액 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1210865B (de) * 1962-03-05 1966-02-17 Fujisawa Pharmaceutical Co Verfahren zur Herstellung des 2, 6-dioxo-tetrahydropyrimidin-4-carbonsauren Salzes des 4-Amino-5-imidazolcarbonsaeureamids
US3997518A (en) * 1970-12-09 1976-12-14 Beecham Group Limited 2-Alkyl-4-carboxyalkyl-5-(3,3'-dimethyltriazeno)-imidazoles
HU190597B (en) * 1983-07-11 1986-09-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing synrtgetic pharmaceutical compositions
US4590201A (en) * 1984-02-02 1986-05-20 Merck & Co., Inc. 5-amino or substituted amino 1,2,3-triazoles
US4847257A (en) * 1987-08-20 1989-07-11 Merck & Co., Inc. 5-Amino or substituted amino 1,2,3,-triazoles useful as antiproliferative agents
US5498620A (en) * 1989-05-19 1996-03-12 The United States Of America As Represented By The Department Of Health And Human Services Signal transduction inhibitor 1,2,3-triazolo compounds
US5132315A (en) * 1989-05-19 1992-07-21 The United States Of America As Represented By The Department Of Health And Human Services Therapeutic application of an anti-invasive compound
US5359078A (en) * 1989-05-19 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Signal transduction inhibitor compounds

Also Published As

Publication number Publication date
CN101273988A (zh) 2008-10-01
KR19990035773A (ko) 1999-05-25
KR100477910B1 (ko) 2005-06-16
US5861406A (en) 1999-01-19
US5728707A (en) 1998-03-17
CN101273988B (zh) 2011-12-14

Similar Documents

Publication Publication Date Title
AR004501A1 (es) Una sal de orotato de un compuesto triazol
CA2227205A1 (en) Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
HK1059044A1 (en) Treatment of statin side effects
NZ544009A (en) Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
NO942376L (no) Terapeutiske midler
TW375615B (en) Galanthamine derivatives and their use as medicaments
IL110328A0 (en) Derivatives of imidazo(1,2,a) pyrazin-4-one, their preparation and medicaments containing them
CA2198580A1 (en) Combination therapy to treat osteoporosis
GB9108629D0 (en) Heterocyclic pharmaceutical compounds,preparation and use
UA37311C2 (uk) Засіб для лікування статевої дисфункції і фармацевтичний препарат
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
NO923413L (no) Terapeutiske benzazepin-forbindelser
EP0581904A4 (en) Method of inhibiting fibrosis
IL124296A0 (en) Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase
WO2003103598A3 (en) AMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOSES
HK1019862A1 (en) Therapeutic anti-asthma agents containing selenium compounds
AU4486796A (en) Imidazole derivatives, their preparation and their use as sadenosylmethionine decarboxylase (=samdc) inhibitors
ES544133A0 (es) Un procedimiento para la preparacion de derivados de imidazol.
DE3365954D1 (en) The use of alpha, alpha-dialkyl adamanthylethylamines to treat measles
CA1272214C (es)
ES8506643A1 (es) Procedimiento para la preparacion de derivados d,l-, d-y l-del acido 3-imidazolil-2-amino-propionico
MY108455A (en) Therapeutic benzazapine compounds.
RU95117234A (ru) Средство и фармацевтическая композиция для лечения заболеваний центральной нервной системы
RU2000102345A (ru) Соединения
TH18310EX (th) วิธีรักษาเนื้องอกที่ต้านยา

Legal Events

Date Code Title Description
FG Grant, registration